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ABSTRACT
Introduction First- trimester pregnancy risk evaluation 
facilitates individualised antenatal care, as well as 
application of preventive strategies for pre- eclampsia 
or birth of a small for gestational age infant. A range of 
early intervention strategies in pregnancies identified as 
high risk at the end of the first trimester has been shown 
to decrease the risk of preterm pre- eclampsia (<37 
gestational weeks). The aim of this project is to create 
the Improving Maternal Pregnancy And Child ouTcomes 
(IMPACT) database; a nationwide database with individual 
patient data, including predictors recorded at the end 
of the first trimester and later pregnancy outcomes, to 
identify women at high risk of pre- eclampsia. A second 
aim is to link the IMPACT database to a biobank with first- 
trimester blood samples.
Methods and analysis This is a Swedish prospective 
multicentre cohort study. Women are included between 
the 11th and 14th weeks of pregnancy. At inclusion, 
pre- identified predictors are retrieved by interviews and 
medical examinations. Blood samples are collected and 
stored in a biobank. Additional predictors and pregnancy 
outcomes are retrieved from the Swedish Pregnancy 
Register. Inclusion in the study began in November 2018 
with a targeted sample size of 45 000 pregnancies by end 
of 2021. Creation of a new risk prediction model will then 
be developed, validated and implemented. The database 
and biobank will enable future research on prediction of 
various pregnancy- related complications.
Ethics and dissemination Confidentiality aspects such 
as data encryption and storage comply with the General 
Data Protection Regulation and with ethical committee 
requirements. This study has been granted national 
ethical approval by the Swedish Ethical Review Authority 
(Uppsala 2018-231) and national biobank approval at 
Uppsala Biobank (18237 2 2018 231). Results from the 
current as well as future studies using information from 
the IMPACT database will be published in peer- reviewed 
journals.
Trial registration number NCT03831490.
INTRODUCTION
First- trimester pregnancy risk evaluation 
facilitates individualised antenatal care. This 
makes it possible to concentrate resources 
on high- risk pregnancies, increasing the 
chance of detecting women at higher risk 
of pregnancy complications already in the 
first trimester, without increasing costs. Early 
interventions may also decrease the risk of 
later complications in some high- risk preg-
nancies, for example, aspirin prophylaxis 
may prevent preterm pre- eclampsia (delivery 
before 37 weeks of gestation),1 progesterone, 
aspirin or omega 3 prophylaxis may prevent 
spontaneous preterm birth,2–4 and limitation 
Strengths and limitations of this study
 ► The Swedish setting, in which antenatal care is free 
of charge, standardised and has virtually 100% cov-
erage among pregnant women, is ideal to create and 
validate prediction models for adverse pregnancy 
events.
 ► The Swedish Pregnancy Register, which automat-
ically retrieves data from computerised standard 
medical records used for antenatal, delivery and 
neonatal care, can facilitate the development of so-
phisticated prediction models.
 ► Connecting a biobank with first- trimester blood 
samples to this database makes it possible to evalu-
ate and add potential new biomarkers to the predic-
tion models, as well as create new future prediction 
models for additional obstetric complications.
 ► The use of a register for outcomes will limit the qual-
ity of the data, but diagnoses will be validated in the 
medical charts to increase specificity.
 ► Differential use of aspirin in the study for high- 
risk women will require that these individuals 
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of gestational weight gain may decrease risks of several 
pregnancy complications.5 6
Pre- eclampsia and birth of a small for gestational age 
(SGA) infant are two major pregnancy complications, in 
which early detection has been shown to be beneficial 
for the mother and the unborn baby.7–9 Furthermore, 
prophylactic intervention with aspirin, prescribed in the 
first trimester to pregnancies identified as high risk, has 
been shown to decrease the incidence of moderate to 
severe pre- eclampsia and SGA requiring delivery before 
37 weeks.10 11 Aspirin also appears to reduce the incidence 
of spontaneous preterm birth.4 High- risk pregnancies can 
be identified in early pregnancy with the Fetal Medicine 
Foundation (FMF) prediction model, a combined model 
using multivariable analysis of maternal factors (maternal 
age, height, weight, Afro, Caribbean or South Asian origin, 
chronic hypertension, systemic lupus erythemathosus, in 
vitro fertilisation, previous pre- eclampsia, family history 
of pre- eclampsia and pregestational diabetes mellitus)12 
and physiological variables reflecting maternal adaption 
to pregnancy such as mean arterial pressure (MAP), 
serum biomarkers and uterine artery Doppler flow.10 
Detection rates and cut- off values have been shown to 
vary among populations when validated in Brazil, Switzer-
land and China,13–15 depending on differences in popu-
lation characteristics, incidence of disease, overfitting of 
the original model and differences in healthcare systems. 
In a recently published study, Asian- specific values had to 
be used in order to increase performance of the predic-
tive model developed in the UK.16 The uterine artery 
Doppler flow can also be hard to reproduce, which was 
shown in the study from Switzerland, where only 43.2% 
was assessed correctly.10 Hence, the model must be vali-
dated in a Swedish population before implementation. 
Sweden has a public health system where antenatal care is 
free and offered to all women facilitating such validation. 
In addition, the FMF model includes expensive covari-
ates, such as several biochemical markers and uterine 
artery Doppler, which can be costly to implement and 
hard to reproduce and to make available for all pregnant 
women.10 13 17 Finally, the predictors included in the FMF 
model do not comprise all known risk factors, either for 
pre- eclampsia or for SGA.18 19
The current risk evaluation for pregnancy complica-
tions in Sweden is generally based on maternal history 
and characteristics. Furthermore, all risk factors are 
treated independently, rendering low sensitivity and spec-
ificity.12 20
The Swedish setting, in which antenatal care is free of 
charge, standardised and has virtually 100% coverage 
among pregnant women, is ideal for creating and vali-
dating prediction models for adverse pregnancy events. 
The Swedish Pregnancy Register, which automatically 
retrieves data from computerised standard medical 
records used for antenatal, delivery and neonatal care, 
can facilitate the development of sophisticated prediction 
models.21 The register includes prospectively collected 
demographic, reproductive and maternal health data, as 
well as information on maternal and neonatal outcomes, 
collected retrospectively. By combining data from the 
Swedish Pregnancy Register with additional data on risk 
factors for pregnancy complications, which are recorded 
but not included in the register, a research database will 
be generated, aiming at creating and validating predic-
tion models for pregnancy complications (table 1).22 
Furthermore, connecting a biobank with first- trimester 
blood samples to this database will enable evaluation and 
addition of potential new biomarkers to the prediction 
models, as well as possible creation of new future predic-
tion models, including for other obstetric complications.
Aims and objectives
The overall aims of this proposal are to improve, optimise 
and equalise antenatal and obstetrical care in order to 
limit adverse maternal and neonatal consequences by:
 ► Constructing a nationwide database with individual 
patient data, including predictors recorded at the 
end of the first trimester and obstetrical outcomes, 
to enable creation and validation of new prediction 
models for different pregnancy complications.
 ► Establishing a biobank with blood samples collected 
in the first trimester with individual linkage to the 
nationwide database.
 ► Creating a Swedish early pregnancy prediction model 
with population- specific risk factors, optimised for the 
Swedish healthcare system and identifying women at 
high risk for pre- eclampsia and SGA, in order to plan 
individualised surveillance for early detection and 
early intervention, which has proven beneficial for 
both mother and infant.7–9
 ► Validating the FMF prediction model for detection of 
pre- eclampsia12 and SGA,23 particularly severe cases 
requiring a preterm delivery, in a Swedish population.
METHODS AND ANALYSIS
Study design and population
A prospective national multicentre cohort study is 
currently being conducted. The cohort forms the 
Improving Maternal Pregnancy And Child ouTcomes 
(IMPACT) database and a biobank is individually linked 
to the database. The study is supported by the Swedish 
Network for National Clinical Studies in Obstetrics and 
Gynecology consortium,39 indicating that it has been 
approved and is included in a network involving all 
obstetrics units in Sweden (cf. Dutch Consortium for 
Healthcare Evaluation and Research in Obstetrics and 
Gynecology—NVOG Consortium 2.0).
Women are approached with information concerning 
the study during their first visit to their antenatal care 
centre. Women with a Swedish personal identity number 
who attend a first- trimester scan at gestational weeks 
11–14 (11 weeks+0 days to 14 weeks+6 days) are eligible 
for inclusion. At present, 75% of obstetrics departments 
in Sweden offer a first- trimester scan (combined ultra-
sound and biochemical screening and/or gestational 
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that are offered a first- trimester scan attend the scan. 
Women are included after receiving written informa-
tion and providing informed consent and are seen once. 
Follow- up data will be retrieved from the Swedish Preg-
nancy Register. Maternal age <18 years and language 
barrier, despite interpreter services and written informa-
tion (available in 11 different languages), are exclusion 
criteria.
IMPACT database
The IMPACT database will comprise data retrieved 
manually that is entered into an enrolment module, 
as well as data routinely collected in the Swedish Preg-
nancy Register (figure 1). The personal identity number 
assigned to all residents of Sweden will be used to cross- 
link the data. The enrolment module includes variables 
identified as potential predictors for pregnancy compli-
cations according to the literature,18 but not already 
available in the Swedish Pregnancy Register. Data are 
collected at an interview and through examinations 
performed during the first- trimester scan visit and regis-
tered in the enrolment module. The interview includes 
data on ethnicity, family history, chronic diseases, current 
aspirin treatment and outcomes of prior pregnancies. 
Examinations include gestational age determination and 
maternal weight, height, blood pressure and pulse rate, 
as well as a blood sample for analysis of serum placental 
growth factor (PlGF) concentration. Gestational age is 
determined by measurement of fetal crown–rump length 
or biparietal diameter and the scans are performed by 
specially trained midwives certified to perform first- 
trimester and second- trimester routine ultrasound scans. 
Maternal pulse rate and blood pressure are measured 
on a validated automatic device (Microlife), according 
to a standardised protocol, two times in both arms with 
appropriate cuff size.24 These measurements are made 
by appropriately trained nurses. MAP is calculated auto-
matically when systolic and diastolic blood pressures are 
recorded in the enrolment module. Pulsatility index 
can be calculated in the first trimester by measuring 
the flow velocity in the ascending branch of the uterine 
artery at the point closest to the internal cervical os with 
transabdominal ultrasound.25 We calculate the uterine 
pulsatility index according to the FMF’s instructions (the 
mean of three measurements in each uterine artery).26 
These measurements are performed by FMF- certified 
examiners and registered in the database. Parallel to 
this, a descriptive study will be conducted, investigating 
how to measure flow resistance in the uterine arteries in 
order to increase reproducibility, previously shown to be 
low.13 The biomarker PlGF is analysed in thawed frozen 
serum samples. The above- mentioned Swedish Pregnancy 
Register currently covers 90% of the Swedish pregnant 
population and reached full national coverage during 
2019.21 Its recorded data include the majority of predic-
tors, without the patient having to undergo any partic-
ular intervention, providing unique opportunities for 
research. The enrolment module and the Swedish Preg-
nancy Register both use MedSciNet as their IT platform,27 
which enables merging of data. Variables in the IMPACT 
database are presented in table 1.
Biobank
At all centres, blood samples are collected at the time 
of the first- trimester ultrasound scan and stored in a 
biobank for future research related to prediction, diag-
nosis and prevention of pregnancy complications. The 
study collects plasma, serum, buffy coat and whole blood, 
and has a multicentre biobank approval. Most centres use 
the Hospital- Integrated Biobank that enables samples to 
be handled in a standardised manner through the hospi-
tals’ clinical laboratories, thus ensuring sample quality. 
IMPACT samples are sent to the local hospital’s clinical 
chemistry laboratory, where they are spun, aliquoted 
and frozen within 4–6 hours, for later shipment to larger 
biobank centres. Samples are only thawed directly prior to 
Figure 1 Study design for the IMPACT database and the IMPACT biobank. IMPACT, Improving Maternal Pregnancy And Child 
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analysis. Each new project utilising the biobank requires 
ethical approval, but no additional informed consent. By 
merging the participants in the biobank with the IMPACT 
database, there will be unique possibilities to explore 
new first- trimester biomarkers for different obstetric and 
neonatal outcomes.
Follow-up of the IMPACT database cohort
We will have the opportunity to follow the cohort in 
Swedish national health and quality registers, enabling 
long- term follow- up for future disease such as chronic 
hypertension and cardiovascular disease.
Validation and creation of prediction models
Candidate predictors
The IMPACT database will include various maternal 
characteristic variables, such as existing chronic disease 
before pregnancy, family history, socioeconomic factors, 
current medication and previous children’s weights and 
gestational ages at birth, which can be applied as contin-
uous, nominal, binary or ordinal variables (table 1). All 
variables included in the FMF model for detection of 
pre- eclampsia and SGA28 will be included in the IMPACT 
database. However, the IMPACT database will also have 
access to candidate predictors not included in the FMF 
prediction model, but shown to be risk factors for pre- 
eclampsia and SGA, for example, maternal renal disease18 
and possibly heart rate29 (table 1). The IMPACT database 
will also include predictors for outcomes of other preg-
nancy complications.
Outcome measures
Data on pregnancy complications will be imported into 
the IMPACT database from the Swedish Pregnancy 
Register. At discharge from hospital after delivery, 
obstetrical complications classified according to the 
Swedish version of the International Classification of 
Diseases, Tenth Revision (ICD-10) will be recorded and 
the information automatically forwarded to the Swedish 
Pregnancy Register. Our main outcome will be preterm 
pre- eclampsia, defined as ICD-10 code O11, O14 or O15 
with delivery before 37 completed weeks of gestation. Our 
secondary outcomes will be risk of overall pre- eclampsia 
and SGA. SGA is defined as birth weight ≤−2 SD from the 
population standard, according to the Swedish reference 
curve for gestational age and fetal sex.30 The outcome 
variables have the potential to be treated either as contin-
uous or binary.
Data processing and analysis
General statistical methodology
In the IMPACT database, we will model the risk of preterm 
pre- eclampsia, overall pre- eclampsia and SGA by using 
multiple regression in order to find the best prediction 
models. Different regression models will be considered 
depending on the type of response variable. These include 
ordinal logistic regression for pre- eclampsia categorised 
by gestational age at delivery, a competing risk model 
for gestational age at delivery with pre- eclampsia as a 
continuous and possibly censored variable, binary logistic 
regression for SGA and linear regression for birth weight 
as a continuous variable, from which the risk of SGA at 
various cut- offs can be computed. All possible predictors 
will first be analysed univariably as the only predictor in 
the model; however, the main focus will be multivariable 
modelling. Depending on the distribution of the vari-
able and its association with the outcome, transforma-
tion may be necessary. Non- linear effects and interaction 
effects of the predictors will also be evaluated for the final 
multivariable model. We will calculate population- based 
multiple of the median reference values for MAP, PlGF 
and uterine pulsatility index. We will consider ongoing 
treatment with aspirin in the analyses. We plan to create 
a prediction model for preterm pre- eclampsia and SGA 
(using two- thirds of the database), as well as to validate 
the risk prediction (using the remaining one- third of the 
database). The discriminative performance of the model 
will be assessed by area under the receiver operating char-
acteristic (ROC), area under the curve (AUC) for binary 
endpoints and by Harrell’s C- statistic for time- to- event 
endpoints with censoring. Harrell’s C- index is a measure 
similar to AUC, after accounting for censoring.29–32 
Women giving birth without pre- eclampsia will be consid-
ered as censored events in the analysis of time- to- delivery 
with pre- eclampsia. A discrimination index less than 0.7 
indicates limited discriminating power, 0.7–0.9 is accept-
able and higher than 0.9 suggests that the predictive 
models have high discriminating power.31
Model development
In developing a multivariable prediction model for gesta-
tional age at delivery with pre- eclampsia, we will consider:
 ► A competing risk model, treating gestational age at 
delivery with pre- eclampsia as a continuous variable 
following a Gaussian distribution.17 Non- events will be 
censored observations.
 ► An ordinal logistic regression model with gestational 
age at delivery with pre- eclampsia categorised by 
gestational age at delivery (<37 weeks, 37<38, 38<39, 
39<40, 40<41 and ≥41 weeks) and no pre- eclampsia.
For development of a multivariable prediction model 
for SGA, we will consider:
 ► A binary logistic regression for SGA.
 ► A linear regression model for birth weight as a contin-
uous variable, from which the risk of SGA at various 
cut- offs can be computed.
For all the models above, a combination of different 
estimation and variable selection techniques will be 
considered, including stepwise selection and penalised 
regression. In addition, a simple recalibration of the FMF 
models12 23 to the current study cohort will be consid-
ered. Two- thirds of the IMPACT database will be used for 
model development, as mentioned above.
Model validation
On completion of the model development phase, a single 
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be chosen for validation on an external dataset (one- 
third of the IMPACT database, as mentioned above). The 
FMF model will also be evaluated on the same dataset.17 
Models will be evaluated with respect to calibration- in- 
the- large (CIL), calibration slope (CS) and discrimina-
tive ability measured as AUC or Harrell’s C- statistic, as 
appropriate. For each of the considered models, calibra-
tion will be assessed graphically with calibration plots and 
evaluated statistically to assess whether CIL  ̸=  0 (system-
atic underestimation/overestimation of absolute risks 
of pre- eclampsia and SGA) or CS  ̸=  1 (prediction model 
is overfitted or underfitted).33 ROC curves will also be 
graphically and statistically compared.
Sample size calculations
A sample size of 45 000 has been chosen to include at least 
10 events per variable in the model development phase,34 
and 100 events in the model validation phase.35 36 These 
calculations are based on an incidence of preterm pre- 
eclampsia of 0.7% in Sweden. This sample size concurs 
with the sample size used for development of the FMF 
model.
Patient and public involvement
No patient nor public was involved in planning of the 
study.
ETHICS AND DISSEMINATION
This is a cohort study with no intervention for the partic-
ipants. Data are stored in a secure online database. 
Biobank samples are identified through the women’s 
personal identification number and pseudonymised after 
identification in the biobank before analysis. Results from 
the study will be published in international peer- reviewed 
journals and a first- trimester risk prediction model will be 
implemented in the Swedish antenatal healthcare setting.
DISCUSSION
The FMF prediction model for detection of preterm pre- 
eclampsia is very promising, but it has not been validated 
in a Swedish setting or adjusted to the Swedish healthcare 
system with its standardised and publicly financed ante-
natal care programme.
This Swedish multicentre IMPACT database will 
include numerous additional predictors of pregnancy 
outcomes and complications. This will enable research 
on various prediction models for different complications 
during pregnancy with a high degree of generalisability, 
due to the national coverage and large sample size. The 
biobank linked to the IMPACT database will further facil-
itate future prediction studies. By linkage to national 
quality and national health registers, we will be able to 
investigate short- term and long- term outcomes for the 
mother and infant. The idea of prospectively including 
research participants in registers has emerged from cardi-
ology research.37 This concept has mostly concerned 
randomised controlled trials and has enabled important 
discoveries that would have been hard to achieve if the 
participants had been included prospectively with sched-
uled follow- ups, which usually means higher loss to 
follow- up and significantly higher costs. These obstacles 
can be overcome by using nationwide Swedish quality and 
health registers. For IMPACT, the women will only need to 
attend one visit occurring in conjunction with their sched-
uled first- trimester ultrasound scan. Therefore, we antici-
pate that most eligible women will consent to participate. 
This will strengthen the internal and external validity of 
the study, as well as facilitate extensive recruitment.
Limitations with this study design include the risk of 
misclassification of diagnoses since these are withdrawn 
from the Pregnancy Register. We will be able to check all 
the pre- eclampsia and gestational hypertension diagnoses 
by review of the medical charts, but we will not detect 
cases where a hypertensive diagnosis has been missed. 
Most of the prediction variables are self- reported by the 
expectant mother and may pose a risk of reporting bias. 
The study nurses are all trained in relevant techniques 
for interviewing expectant mothers about their medical 
history to reduce the risk of misclassification in the enrol-
ment module. For some of the variables in the enrolment 
module, an optional check- box of ‘do not know’ is also 
included to improve the data quality. Another limitation 
with the study is that some women are prescribed aspirin 
prophylaxis due to their high- risk profile. Currently 
according to the Swedish Pregnancy Register, about 2% 
of the Swedish pregnant population take aspirin. These 
women are eligible for the study and information is regis-
tered about aspirin use and dosage. This will be accounted 
for in the statistical analyses.
Today most Swedish women attend a standardised 
antenatal care programme throughout their pregnancy, 
with an increasing number of visits at the end of preg-
nancy. Risk identification in early pregnancy can help 
individualise antenatal care and target women at high 
risk early. High- risk pregnancies can be referred to 
specialised care and normal pregnancies can continue 
in basic antenatal care. Pre- eclampsia is one of the most 
severe consequences of pregnancy and the second most 
common cause of maternal death, leading to substantial 
costs for society related to iatrogenic preterm birth.38 The 
current screening programme for pre- eclampsia lacks 
both sensitivity and specificity. Some women thus attend 
many unnecessary follow- up visits, while diagnosis may be 
delayed for others. To implement individualised care that 
informs both the pregnant woman and the healthcare 
professional about her unique risk profile is of the utmost 
importance, as is future research aiming at improving this 
stratified screening programme further. Knowledge of 
individual risk will improve compliance and target those 
women in need of prophylactic treatment such as aspirin 
to prevent preterm pre- eclampsia.
First- trimester pregnancy risk evaluation with a multi-
variate prediction model will hopefully lead to a cost- 
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all antenatal care centres in the country. Implementation 
will be undertaken as a stepped- wedge cluster randomised 
trial, enabling follow- up of implementation effect in the 
Swedish Pregnancy Register. The main clinical effects will 
be measured as a decreased incidence of preterm pre- 
eclampsia after the risk prediction model is implemented 
and aspirin prophylaxis offered to the identified high- risk 
women (figure 2). In addition, the IMPACT database and 
biobank can be used for future research on prediction 
and prevention of other pregnancy complications.
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